Drugs / Fluoruracil
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02339116 | Feb 2015 → May 2017 | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02506777 Background | Jul 2015 → Aug 2020 | breast cancer | N.N. Petrov National Medical Research Center of Oncology | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06205485 Comparator | Jun 2024 → Jan 2030 expected | rectal cancer | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluoruracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02506777 ↗ |
| Route | Intravenous | “400 mg/m2 intravenous bolus of fluorouracil” PMID 32164906 ↗ Mar 2020 |